share_log

Ensysce Biosciences Announces The Co May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To May 13, 2024 In Order To Demonstrate Compliance With The Equity Requirement In Listing Rule 5550(b)(1)

Benzinga ·  Feb 27 08:11

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment